SCHEMBL369689

SCHEMBL369689

Cc1nc(Nc2nc(-c3cn[nH]c3)cs2)ncc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.53
KCNH2 Q12809 1/20 0.53
GRM8 O00222 1/20 0.41
RAB9A P51151 12/20 0.40
NPC1 O15118 11/20 0.40
TRPV4 Q9HBA0 1/20 0.40
MEN1 O00255 10/20 0.39
KMT2A Q03164 10/20 0.39
SENP8 Q96LD8 3/20 0.39
SENP7 Q9BQF6 3/20 0.39
SENP6 Q9GZR1 3/20 0.39
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NAMPT P43490 3/20 0.38
CASP3 P42574 2/20 0.38
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
APEX1 P27695 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370472 0.84 KCNH2 (0.58) GRM4KCNH2RAB9ANPC1TRPV4
SCHEMBL367343 0.80 GRM4 (0.64) GRM4KCNH2GRM8RAB9ANPC1
SCHEMBL370558 0.79 GRM4 (0.66) GRM4KCNH2GRM8RAB9AMEN1
SCHEMBL371225 0.78 GRM4 (0.72) GRM4KCNH2GRM8RAB9ANPC1
SCHEMBL367423 0.75 GRM4 (0.58) GRM4KCNH2GRM8RAB9ANPC1
SCHEMBL371043 0.74 GRM4 (0.62) GRM4KCNH2RAB9ANPC1TRPV4
SCHEMBL13306645 0.73 KCNH2 (0.57) GRM4KCNH2RAB9ANPC1MEN1
SCHEMBL367354 0.73 GRM4 (0.68) GRM4KCNH2RAB9ANPC1TRPV4
SCHEMBL371035 0.72 KCNH2 (0.63) GRM4KCNH2RAB9ANPC1MEN1
SCHEMBL365863 0.71 NPC1 (0.68) GRM4KCNH2RAB9ANPC1TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073907-B2 Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2015-07-07 US claimed
EP-2376486-B1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2013-11-06 EP claimed
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2011-10-20 US claimed
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM2, GRM1 GRM4 1/4885KCNH2 1489/4885GRM8 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.